Pfizer Faces Federal Probe Over Alleged Election-Time Delay of COVID Vaccine Data
Federal Investigation Launched
Manhattan's federal prosecutors have initiated an investigation into claims made by GSK. The focus is on allegations that Pfizer delayed disclosing the success of its COVID-19 vaccine in 2020. This probe aims to uncover the truth behind the timing of the vaccine's announcement.
GSK Accuses Pfizer of Delaying Announcement
According to the Wall Street Journal, GSK alleges that Pfizer postponed announcing the effectiveness of its COVID-19 shot until after the 2020 election. This delay, if proven, could have significant implications for both companies. GSK's claims have raised questions about Pfizer's intentions during the critical period of vaccine development.
Philip Dormitzer Counters the Allegations
Philip Dormitzer, GSK's former head of vaccine development, has disputed the claims made against Pfizer. He stated that both he and his colleagues at Pfizer worked diligently to secure the FDA's Emergency Use Authorization promptly. Dormitzer emphasized that any interpretation suggesting a deliberate delay is incorrect.
Scope of the Probe by Manhattan Prosecutors
The US Attorney’s Office for the Southern District of New York is thoroughly examining the information provided by GSK. So far, they have interviewed at least two individuals, including a GSK executive who documented a conversation with Dormitzer. The investigation seeks to determine the validity of GSK's allegations against Pfizer.
Repeating Trump's Unsubstantiated Claims
Former President Trump has previously asserted that Pfizer withheld positive data from its vaccine trials. However, these claims have not been supported by concrete evidence. The ongoing investigation aims to address these longstanding accusations and provide clarity on the matter.
Ongoing Developments and Reactions
As the investigation progresses, prosecutors plan to interview a third individual connected to the case. Meanwhile, officials from Pfizer have not yet been questioned by the authorities. GSK has chosen not to comment on the investigation, and neither Pfizer nor the US Attorney’s Office has responded to Reuters' inquiries.
Conclusion
The scrutiny surrounding Pfizer's vaccine announcement highlights the complexities of pharmaceutical communications during a global health crisis. As federal prosecutors delve deeper into the claims, the industry watches closely for outcomes that could influence future practices. Transparency and timely information remain paramount in maintaining public trust.
Read the full article here:
nypost.com